Pretreatment antimicrobial susceptibility testing is not cost saving in the standard eradication of Helicobacter pylori.
Qasim
Asghar
A
Sebastian
Shaji
S
Buckley
Martin
M
O'Connor
Humphrey
H
O'Morain
Colm
C
D000658:Amoxicillin / Q000191:economics / Q000627:therapeutic use; D000897:Anti-Ulcer Agents / Q000191:economics / Q000627:therapeutic use; D017291:Clarithromycin / Q000191:economics / Q000627:therapeutic use; D017046:Cost Savings; D004352:Drug Resistance, Microbial; D004359:Drug Therapy, Combination; D004415:Dyspepsia / Q000188:drug therapy / Q000191:economics; D016481:Helicobacter Infections / Q000188:drug therapy* / Q000191:economics*; D016480:Helicobacter pylori / Q000187:drug effects*; D006801:Humans; D008826:Microbial Sensitivity Tests / Q000191:economics; D054328:Proton Pump Inhibitors; D017494:Proton Pumps / Q000191:economics / Q000627:therapeutic use
D000897:Anti-Ulcer Agents; D054328:Proton Pump Inhibitors; D017494:Proton Pumps; D000658:Amoxicillin; D017291:Clarithromycin